Search results for "From ACP Journal Club"

Results 11 - 20 of about 116 for "From ACP Journal Club".
Sort by: Relevance | Newest | Oldest

In obesity with T2DM, biliopancreatic diversion increased T2DM remission vs. medical and lifestyle therapy at 10 y

Previous research has shown short-term remission of type 2 diabetes after bariatric surgery, but a decade of data from this randomized trial should reassure patients of the favorable long-term benefits and safety of this intervention, an ACP Journal Club commentary said.
11 Jun 2021

In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs

A meta-analysis identified relative benefits of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) based on individual cardiovascular and renal risks.
11 Jun 2021

KDIGO made 12 recommendations for managing diabetes with CKD

The kidney group's guideline supports metformin and sodium–glucose cotransporter-2 inhibitors as first-line therapies for patients with chronic kidney disease (CKD) based on consistent trial data showing their effectiveness, noted an ACP Journal Club commentary.
12 Mar 2021

In men who are overweight or obese, adding testosterone therapy reduced glucose intolerance/T2DM

A industry-funded trial found improved glucose control in men randomized to testosterone injections, but some of its claims were exaggerated, and routine use of testosterone therapy to prevent or reverse type 2 diabetes is not recommended, an ACP Journal Club commentary said.
14 May 2021

In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors

A cohort study's finding of increased risk of diabetic ketoacidosis with sodium-glucose cotransporter-2 (SGLT2) inhibitors is relevant to clinical decision making, but not definitive given the limitations of observational research, an ACP Journal Club commentary said.
8 Jan 2021

GLP-1 RA plus SGLT-2 inhibitor vs. either drug alone reduces HbA1c and SBP

The finding that combining glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors improves glycemic control and systolic blood pressure (SBP) without increasing hypoglycemia is important, but additional cost-effectiveness research on the drugs is needed, an ACP Journal Club commentary said.
11 Dec 2020

In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA1c or significant/severe hypoglycemia

An ACP Journal Club commentary pointed out that use of once-weekly insulin for patients with type 2 diabetes will require more cautious dose-titration algorithms and less stringent glycemic targets to avoid hypoglycemia.
12 Mar 2021

Some glucose-lowering drugs reduce risk for major adverse cardiac events

An umbrella review found cardiovascular benefits from sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, but an ACP Journal Club commentary cautioned that included patients were on a wide array of background treatments.
14 Aug 2020

SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes

Diabetic ketoacidosis (DKA) is rare with sodium-glucose co-transporter-2 (SGLT2) inhibitors but more common than with control medications, and clinicians should be vigilant in identifying euglycemic DKA in patients on these drugs, an ACP Journal Club commentary said.
13 Nov 2020

SGLT2 inhibitors reduce all-cause mortality

A recent meta-analysis found lowered mortality risk with sodium-glucose cotransporter-2 (SGLT2) inhibitors, and an ACP Journal Club commentary added that other trials have shown beneficial effects of the drug class on kidney function in patients with type 2 diabetes.
14 May 2021

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next